Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Antidepressive Agents, Tricyclic × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1 Depressive Disorder 1

Interventions

Cyclophosphamide 2848 Cisplatin 2837 Carboplatin 2635 Radiotherapy 2522 Paclitaxel 2424 Gemcitabine 2263 pembrolizumab 2099 Docetaxel 1978 Bevacizumab 1966 Fluorouracil 1660 Capecitabine 1640 Oxaliplatin 1551 Dexamethasone 1417 Nivolumab 1394 Doxorubicin 1349 Rituximab 1338 Magnetic Resonance Spectroscopy 1229 Etoposide 1198 Irinotecan 1122 Leucovorin 1096 Drug Therapy 1062 Cytarabine 1010 Pemetrexed 944 fludarabine 933 Specimen Handling 875 Vincristine 857 Prednisone 851 Lenalidomide 838 Trastuzumab 837 Cetuximab 831

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡